Skip to main content

Table 2 Meta-analyses on outcomes of parenchymal damage and perioperative outcomes after preoperative chemotherapy with and without bevacizumab for CLM

From: Impact of Bevacizumab on parenchymal damage and functional recovery of the liver in patients with colorectal liver metastases

Histological analyses
  Subgroup SOS Moderate/Severe SOS Hepatic fibrosis Hepatic steatosis
Total - 0.50 [0.37, 0.67] 0.25 [0.17, 0.38]; 0.61 [0.44, 0.86] 0.96 [0.63, 1.45]
p < 0.001; I2 = 0 % p < 0.001; I2 = 0 % p =0.004; I2 = 7 % p = 0.83; I2 = 30 %
No of BEV cycles ≤6 0.50 [0.34, 0.72] 0.21 [0.11, 0.41] 0.60 [0.38, 0.94] 0.94 [0.56, 1.59]
p < 0.001; I2 = 0 % p < 0.001; I2 = 0 % p = 0.03; I2 = 0 % p = 0.82; I2 = 53 %
>6 0.46 [0.21, 1.01] 0.29 [0.10, 0.81] 0.43 [0.19, 1.0] 0.93 [0.34, 2.52]
p = 0.05; I2 = 0 % p = 0.02; I2 = 0 %a p = 0.05; I2 = 0 %b p = 0.89; I2 = 31 %
Time last BEV cycle to surgery ≤8 weeks 0.47 [0.23, 0.95] 0.21 [0.10, 0.47] - -
p = 0.04; I2 = 32 % p < 0.001; I2 = 0 %   
>8 weeks 0.50 [0.28, 0.86] 0.26 [0.12, 0.56] 0.61 [0.34, 1.09] 0.63 [0.21, 1.84]
p = 0.01; I2 = 0 % p < 0.001; I2 = 0 % p = 0.09; I2 = 0 % p = 0.39; I2 = 45 %
Cytotoxic chemotherapy4 Oxaliplatin high 0.46 [0.21, 1.01] 0.29 [0.10, 0.81] 0.43 [0.19, 1.00] 0.93 [0.34, 2.52]
p = 0.05; I2 = 0 % p = 0.02; I2 = 0 %a p = 0.05; I2 = 0 %b p = 0.89; I2 = 31 %
Oxaliplatin low 0.51 [0.37, 0.69] 0.25 [0.16, 0.38] 0.52 [0.37, 0.75] 0.94 [0.56, 1.59]
p < 0.001; I2 = 0 % p < 0.001; I2 = 0 % p < 0.001; I2 = 0 % p = 0.82; I2 = 53 %
Functional Recovery and Perioperative Outcome
   Morbidity Wound complications Liver failure Mortality
Total - 1.10 [0.88, 1.37] 1.81 [1.12, 2.91] 0.61 [0.34, 1.07] 0.60 [0.20, 1.82]
p = 0.39; I2 = 10 % p = 0.02; I2 = 4 % p = 0.08; I2 = 6 % p = 0.37; I2 = 0 %
No of BEV cycles ≤6 0.99 [0.75, 1.30] 1.22 [0.61, 2.42] 0.49 [0.21, 1.14] 0.54 [0.10, 2.93]
p = 0.95; I2 = 0 % p = 0.58; I2 = 0 %c p = 0.10; I2 = 0 % p = 0.47; I2 = 0 %
>6 1.51 [1.08, 2.13] 1.88 [0.89, 3.99] 0.85 [0.36, 2.00] 0.46 [0.09, 2.41]
p = 0.02; I2 = 0 % p = 0.10; I2 = 0 % p = 0.71; I2 = 16 % p = 0.36; I2 = 0 %
Time last BEV cycle to surgery ≤8 weeks 1.06 [0.70, 1.59] 1.59 [0.50, 5.11] 0.50 [0.16, 1.57] 1.16 [0.14, 9.37]
p = 0.80; I2 = 33 % p = 0.43; I2 = 0 % p = 0.24; I2 = 0 % p = 0.89; I2 = 0 %
>8 weeks 1.27 [0.92, 1.74] 1.45 [0.84, 2.50] 0.70 [0.32, 1.51] 0.47 [0.13, 1.71]
p = 0.15; I2 = 0 % p = 0.19; I2 = 0 % p = 0.36; I2 = 23 % p = 0.25; I2 = 0 %
Cytotoxic chemotherapyd Oxaliplatin high 1.19 [0.87, 1.63] 1.47 [0.87, 2.49] 0.61 [0.28, 1.30] 0.55 [0.14, 2.19]
p = 0.28; I2 = 17 % p = 0.15; I2 = 0 % p = 0.20; I2 = 29 % p = 0.40; I2 = 0 %
Oxaliplatin low 1.01 [0.74, 1.38] 3.19 [0.82, 12.35] 0.50 [0.16, 1.59] 0.70 [0.11, 4.47]
p = 0.95; I2 = 6 % p = 0.09; I2 = 51 % p = 0.24; I2 = 0 % p = 0.71; I2 = 0 %
  1. aResults of sensitivity analyses after exclusion of the study by Aussilhou et al. [20]
  2. bResults of sensitivity analyses after exclusion of the study by Wicherts et al. [33]
  3. cResults of sensitivity analyses after exclusion of the study by Rong et al. [28]
  4. dThe subgroup analysis on the kind of systemic chemotherapy administered was based on the fraction of patients who received oxaliplatin or irinotecan. Studies in the oxaliplatin high group had > 76 % of patients who received oxaliplatin, whereas studies in the oxaliplatin low had ≤ 76 % patients with oxaliplatin. This cut-off was chosen based on the average proportion of patients with oxaliplatin in each study
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us

\